Challenges and perspectives in the immunotherapy of Hodgkin lymphoma
- 1 November 2017
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 85, 67-77
- https://doi.org/10.1016/j.ejca.2017.08.014
Abstract
No abstract availableThis publication has 76 references indexed in Scilit:
- Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin LymphomaJournal of Clinical Oncology, 2013
- Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?Science, 2013
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort StudyJournal of Clinical Oncology, 2012
- Irradiation Promotes an M2 Macrophage Phenotype in Tumor HypoxiaFrontiers in Oncology, 2012
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaBlood, 2011
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactionsInternational Journal of Cancer, 2007